Riedel A, Schneider S, Mest H J
Department of Pharmacology and Toxicology, Martin Luther University, Halle-Wittenberg, GDR.
Biomed Biochim Acta. 1988;47(10-11):S27-30.
Substances shifting the balance between thromboxane (TX) and prostacyclin (PGI2) in favour of PGI2 could be of therapeutic value for arrhythmia treatment. This seems to be independent of the pathogenetic mechanism. The TX receptor antagonist BM 13177, the lipoxygenase inhibitor esculetin were effective in ouabain and aconitine induced arrhythmias while the PGI2 formation stimulating substance nafazatrom was only effective in aconitine induced arrhythmia. BM 13177 and esculetin could also counteract the arrhythmogenic effect of PAF. TX synthetase inhibition by HOE 944 was ineffective or partially effective, resp..
使血栓素(TX)和前列环素(PGI2)之间的平衡向有利于PGI2的方向转变的物质可能对心律失常的治疗具有治疗价值。这似乎与发病机制无关。TX受体拮抗剂BM 13177、脂氧合酶抑制剂七叶亭对哇巴因和乌头碱诱发的心律失常有效,而刺激PGI2形成的物质萘呋胺酯仅对乌头碱诱发的心律失常有效。BM 13177和七叶亭也可以抵消PAF的致心律失常作用。HOE 944对TX合成酶的抑制作用分别无效或部分有效。